JP6441792B2 - Ｅｇｆｒに結合する抗原結合蛋白質 - Google Patents

Ｅｇｆｒに結合する抗原結合蛋白質 Download PDF

Info

Publication number
JP6441792B2
JP6441792B2 JP2015512727A JP2015512727A JP6441792B2 JP 6441792 B2 JP6441792 B2 JP 6441792B2 JP 2015512727 A JP2015512727 A JP 2015512727A JP 2015512727 A JP2015512727 A JP 2015512727A JP 6441792 B2 JP6441792 B2 JP 6441792B2
Authority
JP
Japan
Prior art keywords
seq
sequence number
egfr
antibody
referred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015512727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518827A5 (enExample
JP2015518827A (ja
Inventor
ヘユー・ジョウ
ランディ・ギャストワート
バーバラ・エイ・スワンソン
ジョン・ディクソン・グレイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2015518827A publication Critical patent/JP2015518827A/ja
Publication of JP2015518827A5 publication Critical patent/JP2015518827A5/ja
Application granted granted Critical
Publication of JP6441792B2 publication Critical patent/JP6441792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015512727A 2012-05-17 2013-05-13 Ｅｇｆｒに結合する抗原結合蛋白質 Expired - Fee Related JP6441792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648391P 2012-05-17 2012-05-17
US61/648,391 2012-05-17
PCT/US2013/040827 WO2013173255A2 (en) 2012-05-17 2013-05-13 Antigen binding proteins that bind egfr

Publications (3)

Publication Number Publication Date
JP2015518827A JP2015518827A (ja) 2015-07-06
JP2015518827A5 JP2015518827A5 (enExample) 2016-06-30
JP6441792B2 true JP6441792B2 (ja) 2018-12-19

Family

ID=49581478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512727A Expired - Fee Related JP6441792B2 (ja) 2012-05-17 2013-05-13 Ｅｇｆｒに結合する抗原結合蛋白質

Country Status (7)

Country Link
US (1) US9944707B2 (enExample)
EP (1) EP2850105A4 (enExample)
JP (1) JP6441792B2 (enExample)
CN (1) CN104918956A (enExample)
CA (1) CA2872018A1 (enExample)
HK (1) HK1208474A1 (enExample)
WO (1) WO2013173255A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
EP3280442A4 (en) * 2015-04-08 2018-10-31 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd123
MX2018007406A (es) * 2015-12-16 2018-08-15 Merck Sharp & Dohme Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
AR107505A1 (es) 2016-01-22 2018-05-09 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulación xi
EP3449939B1 (en) 2016-04-27 2022-03-30 Green Cross Corporation Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor
KR102218714B1 (ko) 2016-06-14 2021-02-24 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
EP3980448A4 (en) * 2019-06-04 2023-06-28 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
WO2021035096A1 (en) * 2019-08-20 2021-02-25 Kumquat Biosciences Inc. Compositions and methods for targeting cellular molecules
WO2022251575A1 (en) * 2021-05-27 2022-12-01 The United States Government As Represented By The Department Of Veterans Affairs Human monoclonal antibodies specific to streptolysin o and methods of use
CA3243690A1 (en) * 2022-02-04 2023-08-10 Vivasor Inc ANTIGEN-BINDING PROTEINS THAT BIND TO B7-H3

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221001B1 (hu) * 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
EP2111870A1 (en) 1999-08-27 2009-10-28 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
CZ200438A3 (cs) * 2001-06-13 2004-06-16 Genmab A/S Název neuveden
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
SI1735348T1 (sl) * 2004-03-19 2012-09-28 Imclone Llc Äśloveĺ ko anti-egfr protitelo
WO2005090407A1 (en) * 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
EP2402374A1 (en) * 2005-02-07 2012-01-04 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2007058823A2 (en) 2005-11-12 2007-05-24 Eli Lilly And Company Anti-egfr antibodies
US20100291593A1 (en) 2007-07-13 2010-11-18 Powell William C Method of identifying diagnostic reagents
CN102164960A (zh) 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
JPWO2010087425A1 (ja) 2009-01-30 2012-08-02 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
AU2010230346A1 (en) 2009-03-31 2011-07-28 Roche Glycart Ag Treatment of cancer with a humanized anti-EGFR IgG1antibody and irinotecan
ES2639056T3 (es) 2009-10-28 2017-10-25 Abbvie Biotherapeutics Inc. Anticuerpos anti-EGFR y sus usos
JP5818003B2 (ja) 2009-11-18 2015-11-18 国立大学法人東北大学 ヒト型化抗ｅｇｆｒ抗体可変領域の高機能性変異体
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
AU2011320314B2 (en) * 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
TWI443108B (zh) 2011-12-28 2014-07-01 Ind Tech Res Inst 抗人類表皮生長因子受體抗體及其應用

Also Published As

Publication number Publication date
EP2850105A2 (en) 2015-03-25
WO2013173255A2 (en) 2013-11-21
US9944707B2 (en) 2018-04-17
CA2872018A1 (en) 2013-11-21
EP2850105A4 (en) 2016-03-16
JP2015518827A (ja) 2015-07-06
CN104918956A (zh) 2015-09-16
HK1208474A1 (en) 2016-03-04
US20130309233A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
JP6829330B2 (ja) Ｐｄ−ｌ１に結合する抗原結合蛋白質
JP6997743B2 (ja) Ｐｄ－１に結合する抗原結合蛋白質
US11919952B2 (en) Antigen binding proteins that bind PD-L1
US12084503B2 (en) Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2) and methods of use thereof for treatment
JP6441792B2 (ja) Ｅｇｆｒに結合する抗原結合蛋白質
JP2015518827A5 (enExample)
CN105120890B (zh) 与ErbB3结合的抗原结合蛋白
JP2015520172A (ja) Ｄｌｌ−４に結合する抗原結合蛋白質
CN104411332B (zh) 与vegfr2结合的全人抗体
JP6388576B2 (ja) Ｉｇｆ１ｒに結合する抗原結合タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181122

R150 Certificate of patent or registration of utility model

Ref document number: 6441792

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees